Abe Koichiro, Yamamoto Takatsugu, Matsumoto Kotaro, Kikuchi Kentaro, Miura Ryo, Tachizawa Naoko, Asaoka Yoshinari, Takezawa Tomoko, Matsunaga Naohisa, Obi Shuntaro, Tanaka Atsushi
Department of Medicine, Teikyo University School of Medicine, Japan.
Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan.
Intern Med. 2020;59(19):2353-2358. doi: 10.2169/internalmedicine.5777-20. Epub 2020 Oct 1.
Objective Liver injury is a notable complication of coronavirus disease 2019 (COVID-19). This study aimed to clarify the clinical features and liver injury in Japanese patients with COVID-19. Methods We conducted a multicenter retrospective cohort study. All consecutive patients with COVID-19 who visited or were admitted to our hospital before May 12, 2020, were enrolled. Their demographics, symptoms, laboratory findings, comorbidities, concomitant drugs, treatment, and clinical course were reviewed. We defined liver injury as alanine aminotransferase (ALT) or gamma-glutamyl transferase (GGT) levels over the upper limit of normal. Results Twenty-two patients with COVID-19 (median age, 47 years old; men/women, 13/9) were enrolled. Two patients had underlying liver diseases, and two were diagnosed as having COVID-19 without any symptoms. Elevated ALT and GGT levels were found in 12 and 12 patients, respectively, and liver injury was observed in 15 patients (68.2%). Compared with the patients without liver injury, those with liver injury had a significantly higher fever during the clinical course (median, 37.5°C vs. 38.8°C, p=0.006). A significant correlation was found between the highest serum liver values and the highest body temperature in each patient. Among the 22 patients, 4 required artificial respiratory support, and 2 died thereafter. Liver injury was not associated with the severity or mortality of COVID-19. Conclusion Elevated levels of liver enzymes in the Japanese patients with COVID-19 were associated with the highest body temperature during the clinical course but not with the severity or mortality of COVID-19.
目的 肝损伤是2019冠状病毒病(COVID-19)的一种显著并发症。本研究旨在阐明日本COVID-19患者的临床特征和肝损伤情况。方法 我们进行了一项多中心回顾性队列研究。纳入了2020年5月12日前到我院就诊或住院的所有连续COVID-19患者。回顾了他们的人口统计学特征、症状、实验室检查结果、合并症、伴随用药、治疗及临床病程。我们将肝损伤定义为丙氨酸氨基转移酶(ALT)或γ-谷氨酰转移酶(GGT)水平超过正常上限。结果 纳入了22例COVID-19患者(中位年龄47岁;男/女,13/9)。2例患者有基础肝病,2例无症状COVID-19患者。分别有12例和12例患者ALT和GGT水平升高,15例患者(68.2%)出现肝损伤。与无肝损伤患者相比,有肝损伤患者在临床病程中发热明显更高(中位值,37.5℃对38.8℃,p = 0.006)。发现每位患者的最高血清肝酶值与最高体温之间存在显著相关性。22例患者中,4例需要人工呼吸支持,其中2例随后死亡。肝损伤与COVID-19的严重程度或死亡率无关。结论 日本COVID-19患者肝酶水平升高与临床病程中的最高体温有关,但与COVID-19的严重程度或死亡率无关。